Target (TGT) Reports $752 Million Earnings Boost from Tariff Refunds, Adjusts Full-Year Outlook
Moderna's shares surged following positive results from its cancer vaccine trial, while rising bond yields are raising concerns about consumer loans and government debt. Investors should also note Target's earnings boost from tariff refunds and the implications of paused tariffs on Canadian goods.